P26006 Pre – Assessment – Medical Learning Institute Inc

Pre-Assessment

Name

First

Last

Email

NPI #

Meeting Location

is endocrine reveals:

If other please describe:

What is your primary specialty?

Oncology
Other (please specify below)

If other please describe:

1. Which of the following clinicopathologic features most strongly identifies patients with HR+ HER2- EBC as having a high risk of recurrence despite receiving standard endocrine therapy?

A. Ki-67 ≥20%
B. Premenopausal status and age
C. Tumor grade and ≥1 positive node
D. Tumor size >2 cm

Please select the extent to which you feel confident in your answer:

Completely Confident	Fairly Confident	Somewhat Confident	Slightly Confident	Not Confident
Completely ConfidentCompletely Confident	Fairly ConfidentFairly Confident	Somewhat ConfidentSomewhat Confident	Slightly ConfidentSlightly Confident	Not ConfidentNot Confident

2. Your patient, Bonnie, a 55-year-old postmenopausal woman, undergoes lumpectomy for HR+ HER2- invasive ductal carcinoma. Pathology reveals: tumor size: 1.5 cm, grade 3, Ki-67 = 15%, 0 of 3 sentinel lymph nodes involved, clear margins. She completes post-surgical adjuvant chemotherapy and is planned for endocrine therapy. Based on clinical recommendations, which of the following is the most appropriate systemic strategy?

A. Aromatase inhibitor as endocrine therapy
B. Aromatase inhibitor combined with abemaciclib
C. Ovarian suppression plus aromatase inhibitor combined with a CDK4/6 inhibitor
D. Tamoxifen regimen followed by an aromatase inhibitor

Please select the extent to which you feel confident in your answer:

Completely Confident	Fairly Confident	Somewhat Confident	Slightly Confident	Not Confident
Completely ConfidentCompletely Confident	Fairly ConfidentFairly Confident	Somewhat ConfidentSomewhat Confident	Slightly ConfidentSlightly Confident	Not ConfidentNot Confident

3. According to current management recommendations, what is the appropriate initial management strategy for Grade 2 diarrhea (>24 hours) associated with adjuvant abemaciclib therapy?

A. Continue abemaciclib at the same dose and escalate antidiarrheal treatment
B. Discontinue abemaciclib due to gastrointestinal toxicity
C. Suspend dose until resolution as no abemaciclib dose reduction is required if symptoms do not persist
D. Interrupt abemaciclib until diarrhea resolves to ≤Grade 1, then resume at the next lower dose level

Please select the extent to which you feel confident in your answer:

Completely Confident	Fairly Confident	Somewhat Confident	Slightly Confident	Not Confident
Completely ConfidentCompletely Confident	Fairly ConfidentFairly Confident	Somewhat ConfidentSomewhat Confident	Slightly ConfidentSlightly Confident	Not ConfidentNot Confident

4. Another one of your patients, Greta, a 59-year-old postmenopausal woman with node-positive, high-risk HR+ HER2- EBC, is receiving endocrine therapy plus abemaciclib. Her medical history includes atrial fibrillation and hyperlipidemia. Her current medications include: apixaban, atorvastatin, diltiazem, and omeprazole. At today’s visit, she reports that her PCP recently prescribed clarithromycin for community-acquired pneumonia. Which of the following is the most appropriate management strategy?

A. Continue medications as prescribed, as no clinically meaningful interactions are expected
B. Discontinue apixaban during clarithromycin therapy to reduce bleeding risk
C. Reduce the dose of abemaciclib while she is receiving clarithromycin
D. Temporarily hold endocrine therapy but continue abemaciclib and clarithromycin

Please select the extent to which you feel confident in your answer:

Completely Confident	Fairly Confident	Somewhat Confident	Slightly Confident	Not Confident
Completely ConfidentCompletely Confident	Fairly ConfidentFairly Confident	Somewhat ConfidentSomewhat Confident	Slightly ConfidentSlightly Confident	Not ConfidentNot Confident

5. Which of the following evidence-based strategies is most effective for improving long-term adherence and persistence with adjuvant CDK4/6 inhibitor therapy?

A. Encourage patients to manage mild adverse events unless symptoms become severe.
B. Implement structured patient education with proactive toxicity management and regular follow-up.
C. Provide detailed written education about dosing schedules and potential adverse events of treatment.
D. Use routine dose interruptions when adverse events occur as necessary.

Please select the extent to which you feel confident in your answer:

Completely Confident	Fairly Confident	Somewhat Confident	Slightly Confident	Not Confident
Completely ConfidentCompletely Confident	Fairly ConfidentFairly Confident	Somewhat ConfidentSomewhat Confident	Slightly ConfidentSlightly Confident	Not ConfidentNot Confident

6. Your patient Michelle, a 42-year-old premenopausal woman with HR+ HER2– EBC, has been receiving endocrine therapy plus ribociclib for 4 months. At a routine follow-up visit, she reports mild fatigue but denies palpitations, syncope, or infection symptoms. To safely manage potential ribociclib-associated toxicities and support treatment continuation, which of the following multidisciplinary care team configurations is most appropriate to proactively address adverse-event monitoring?

A. Oncology dietitian, survivorship counselor, and physical therapist
B. Oncology nurse navigator, clinical pharmacist, and cardiologist
C. Oncology nurse navigator, palliative care physician, and behavioral health specialist
D. Radiation oncologist, survivorship counselor, and oncology social worker

Please select the extent to which you feel confident in your answer:

Completely Confident	Fairly Confident	Somewhat Confident	Slightly Confident	Not Confident
Completely ConfidentCompletely Confident	Fairly ConfidentFairly Confident	Somewhat ConfidentSomewhat Confident	Slightly ConfidentSlightly Confident	Not ConfidentNot Confident

7. How confident are you in your ability to apply evidence-based CDK4/6 inhibitor–containing adjuvant therapy in patients with high-risk HR+ HER2- EBC?